Pernix Therapeutics Inc. to Present at the Deutsche Bank Pharma 1-on-1 Day in Denver, Colorado

MORRISTOWN, N.J.--(BUSINESS WIRE)--

Pernix Therapeutics Holdings, Inc. PTX, a specialty pharmaceutical company, announced today that Sanjay Patel, Chief Financial Officer, will present an update on the company at the Pharma 1-on-1 Day sponsored by Gregg Gilbert from Deutsche Bank on Thursday March 26, 2015 in Denver, Colorado.

The presentation will be available on the Pernix Therapeutics website at www.pernixtx.comby navigating to "Investor Relations," and then "Webcasts and Presentations" and will be archived there for future reference.

About Pernix Therapeutics

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

The presentation mentioned in this press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because these statements reflect the Company's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in the Company's Annual Report on Form 10-K.

To learn more about Pernix Therapeutics, visit www.pernixtx.com.